A detailed history of Srs Capital Advisors, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 42 shares of REGN stock, worth $43,970. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42
Previous 14 200.0%
Holding current value
$43,970
Previous $13,000 238.46%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$883.2 - $1071.19 $24,729 - $29,993
28 Added 200.0%
42 $44,000
Q4 2023

Feb 06, 2024

SELL
$775.18 - $881.7 $775 - $881
-1 Reduced 6.67%
14 $12,000
Q3 2023

Nov 14, 2023

BUY
$692.45 - $844.37 $692 - $844
1 Added 7.14%
15 $12,000
Q2 2023

Aug 14, 2023

SELL
$700.03 - $830.35 $700 - $830
-1 Reduced 6.67%
14 $10,000
Q1 2023

May 16, 2023

BUY
$680.49 - $826.97 $2,721 - $3,307
4 Added 36.36%
15 $12,000
Q4 2022

Feb 24, 2023

BUY
$705.89 - $766.39 $705 - $766
1 Added 10.0%
11 $7,000
Q3 2022

Nov 03, 2022

BUY
$573.97 - $724.32 $3,443 - $4,345
6 Added 150.0%
10 $7,000
Q2 2022

Aug 22, 2022

BUY
$548.35 - $738.84 $1,096 - $1,477
2 Added 100.0%
4 $2,000
Q1 2022

May 12, 2022

SELL
$595.12 - $698.43 $1,190 - $1,396
-2 Reduced 50.0%
2 $1,000
Q4 2021

Feb 08, 2022

BUY
$543.48 - $670.97 $1,086 - $1,341
2 Added 100.0%
4 $3,000
Q3 2021

Nov 05, 2021

BUY
$574.03 - $680.96 $1,148 - $1,361
2 New
2 $1,000
Q3 2018

Nov 06, 2018

SELL
$351.14 - $408.51 $3,511 - $4,085
-10 Closed
0 $0
Q2 2018

Aug 21, 2018

SELL
$284.6 - $344.99 $3,130 - $3,794
-11 Reduced 52.38%
10 $3,000
Q1 2018

May 14, 2018

SELL
$315.82 - $393.78 $20,528 - $25,595
-65 Reduced 75.58%
21 $7,000
Q4 2017

Feb 15, 2018

SELL
$358.63 - $469.95 $3,944 - $5,169
-11 Reduced 11.34%
86 $32,000
Q3 2017

Nov 15, 2017

BUY
$431.38 - $504.0 $41,843 - $48,888
97
97 $43,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $112B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Srs Capital Advisors, Inc. Portfolio

Follow Srs Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Srs Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Srs Capital Advisors, Inc. with notifications on news.